SR 878
Alternative Names: SR-878Latest Information Update: 14 Jul 2024
At a glance
- Originator SciRhom
- Class Anti-inflammatories; Antibodies; Antirheumatics; Monoclonal antibodies
- Mechanism of Action RHBDF2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 09 Jul 2024 SciRhom plans a clinical trial (In volunteers) in Austria in the second half of 2024 (Parenteral)
- 12 Jun 2024 Austrian regulatory authorities approves clinical trial application for SR 878
- 12 Jun 2024 Safety and pharmacodynamics data from a preclinical trial in Autoimmune disorders and Rheumatoid arthritis released by SciRhom